Introduction to Amino Acids: Building Blocks,...

Amino acids are among the most fundamental molecules in human biology. They underpin the structure of every protein in the body, serve as direct signalling molecules, fuel metabolic pathways, and act as precursors to neurotransmitters, hormones, and other bioactive compounds. Despite their centrality, amino acids remain underrepresented in routine health monitoring — even as growing evidence connects circulating amino acid profiles to metabolic health, tissue integrity, and longevity.

This article explores the biology of amino acids, their specific functional roles, the conditions under which imbalances may arise, and why liquid chromatography-tandem mass spectrometry (LC-MS/MS) has emerged as the method of choice for measuring them with clinical precision.

1. What Are Amino Acids?

Amino acids are small organic molecules defined by a shared core structure: a central carbon atom (the alpha carbon) bonded to an amino group (–NH₂), a carboxyl group (–COOH), a hydrogen atom, and a variable side chain (R group) that determines each molecule's chemical identity and function. It is this side chain that differentiates, for example, the simple glycine from the branched leucine or the aromatic tryptophan.

Twenty standard amino acids are encoded by the human genome and incorporated into proteins during translation. Beyond their structural role, a subset of these amino acids — and several non-proteinogenic derivatives — function as signalling molecules, neurotransmitter precursors, substrates for energy metabolism, and regulators of gene expression.

Amino acids are conventionally grouped into three categories based on biosynthetic capacity:

Essential amino acids (EAAs): Cannot be synthesised by the human body in adequate quantities and must be obtained through diet. There are nine: histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine.
Non-essential amino acids (NEAAs): Can be synthesised endogenously from precursors under normal physiological conditions. Examples include alanine, asparagine, aspartate, and glutamate.
Conditionally essential amino acids: Typically synthesisable, but may become limiting under states of physiological stress, illness, rapid growth, or compromised metabolic function. Key examples include glutamine, arginine, tyrosine, cysteine, proline, and serine.

2. From Amino Acids to Peptides and Proteins: The Biochemical Hierarchy

Understanding how amino acids relate to peptides and proteins requires appreciating a fundamental biochemical hierarchy. Amino acids are the monomeric units; when two or more are joined by peptide bonds (covalent links between the carboxyl group of one residue and the amino group of the next), a chain is formed. The terminology follows the length of the chain:

Dipeptides and tripeptides contain two or three amino acid residues respectively.
Oligopeptides typically contain up to approximately 20 residues and may have distinct biological activity — for instance, the tripeptide glutathione (glutamate–cysteine–glycine), a central antioxidant molecule.
Polypeptides contain larger chains and begin to fold into three-dimensional structures.
Proteins are fully folded, functional macromolecules — often composed of one or more polypeptide chains — that carry out enzymatic, structural, transport, immune, and regulatory functions throughout the body.

The distinction matters analytically. Free amino acids circulating in plasma represent the pool immediately available for metabolic use — they are not yet incorporated into protein structure and can be directly quantified as individual molecules. This circulating pool reflects dietary intake, protein catabolism, de novo biosynthesis, and interorgan exchange fluxes simultaneously, making it an informative window into the body's overall nitrogen and metabolic status.

3. Key Amino Acids and Their Biological Roles

While all amino acids are biologically relevant, a subset has been particularly well-characterised as biomarkers or functional molecules with direct implications for health and performance.

Branched-Chain Amino Acids (BCAAs): Leucine, Isoleucine, Valine

The BCAAs are unique among essential amino acids in that they are catabolised primarily in skeletal muscle rather than the liver. Leucine in particular functions not only as a substrate for muscle protein synthesis but as a direct signalling molecule activating the mTOR (mammalian target of rapamycin) pathway, a central regulator of anabolic metabolism. Research suggests that a threshold leucine concentration — often cited in the range of 2–3 g per meal — is required to maximally stimulate muscle protein synthesis. Valine and isoleucine contribute to energy production during prolonged exercise. BCAA plasma profiles have also been linked to insulin resistance risk, with chronically elevated BCAAs observed in metabolic syndrome and type 2 diabetes, likely reflecting impaired BCAA catabolism.

Tryptophan

Tryptophan is the sole dietary precursor to serotonin — a neurotransmitter with broad roles in mood regulation, gastrointestinal motility, and sleep architecture — and to melatonin, the circadian rhythm hormone. A second major catabolic route, the kynurenine pathway, generates NAD⁺ precursors via nicotinamide riboside and nicotinamide mononucleotide intermediates, establishing a biochemical link between tryptophan availability and cellular energy metabolism. Tryptophan is the least abundant essential amino acid in most dietary proteins, making it a meaningful measurement target.

Phenylalanine and Tyrosine

Phenylalanine is an essential amino acid that is hydroxylated to tyrosine — a conditionally essential amino acid — via phenylalanine hydroxylase, an enzyme requiring tetrahydrobiopterin (BH₄) as a cofactor. Tyrosine in turn is a precursor to the catecholamines (dopamine, norepinephrine, epinephrine) and to thyroid hormones. An elevated phenylalanine:tyrosine ratio may reflect impaired hydroxylation and has been studied in inflammatory conditions and hepatic dysfunction.

Methionine and Cysteine

Methionine is the initiator of most protein synthesis and the primary methyl-group donor in one-carbon metabolism, operating through S-adenosylmethionine (SAM). Its metabolism is tightly linked to homocysteine cycling — a key cardiovascular and methylation biomarker. Cysteine, derived in part from methionine via the transsulfuration pathway, is a rate-limiting precursor to glutathione, the body's primary intracellular antioxidant.

Glutamine

Glutamine is the most abundant free amino acid in plasma and muscle tissue. It serves as the primary fuel for rapidly dividing cells including enterocytes and immune cells, and plays a central role in nitrogen transport between tissues, acid-base balance (via renal ammonia excretion), and gluconeogenesis during fasting or stress. Plasma glutamine levels can fall substantially during prolonged critical illness, major surgery, or extreme endurance exercise, raising its status as a conditionally essential amino acid in high-demand contexts.

Arginine

Arginine is a substrate for nitric oxide (NO) synthesis via nitric oxide synthase, linking it to endothelial function, blood pressure regulation, and immune response. It is also a central intermediate in the urea cycle and a precursor to creatine, a key energy buffer in skeletal and cardiac muscle. Arginine availability is often conditionally limiting in cardiovascular disease, sepsis, and post-surgical recovery.

Glycine

Glycine is the smallest amino acid and a structural component of collagen — the most abundant protein in the human body. It also functions as an inhibitory neurotransmitter in the central nervous system and is required for glutathione and creatine biosynthesis. Endogenous glycine synthesis may not fully meet requirements under high collagen turnover or synthesis demands, and glycine has attracted research interest in the context of longevity and insulin sensitivity.

4. Amino Acid Status: Imbalance in Context

A key consideration that distinguishes amino acids from many other micronutrients is that most healthy individuals with adequate and varied food intake will maintain circulating amino acid levels within a broadly normal range. Unlike, for example, vitamin D — which is difficult to obtain solely from food and is widely deficient across populations — or iron — which can be depleted by blood loss, malabsorption, or menstruation — amino acids are typically replenished through daily protein consumption. A diet providing sufficient total protein from diverse sources generally supplies the full spectrum of essential amino acids without the need for supplementation.

That said, the concept of sufficiency is not the same as optimisation. Several contexts exist where amino acid monitoring becomes genuinely relevant:

Inadequate total protein intake: Common in older adults, restrictive dietary patterns (particularly poorly planned vegan diets), and populations with reduced appetite or food access.
Impaired absorption: Inflammatory bowel disease, coeliac disease, or post-surgical anatomy can compromise amino acid uptake.
Inborn errors of metabolism: Conditions such as phenylketonuria (PKU) involve defects in specific amino acid metabolism — phenylalanine accumulation in PKU is a classical clinical example.
Hepatic and renal dysfunction: The liver is central to amino acid catabolism and redistribution; severe liver disease disrupts BCAA:aromatic amino acid ratios (the Fischer ratio) in clinically meaningful ways.

Beyond correcting deficiency, optimisation of amino acid intake and status is an active area — particularly in athletic performance. The leucine threshold model of muscle protein synthesis has driven substantial interest in BCAA supplementation strategies, particularly in the context of recovery nutrition, protein timing, and resistance training. Research suggests that leucine-enriched protein sources — or targeted BCAA supplements — may offer advantages in maximising anabolic signalling per gram of protein, especially in older individuals where the anabolic response to protein is blunted.

5. Amino Acids Under Specific Protocols

Several pharmacological and clinical contexts warrant particular attention to amino acid status — not because amino acid deficiency is universally expected, but because the physiological or nutritional shifts they involve may increase the relevance of monitoring.

GLP-1 Receptor Agonists

GLP-1 receptor agonists — including semaglutide and other agents in this class — are now widely prescribed for obesity and type 2 diabetes management. Their effectiveness in promoting weight loss is substantially driven by appetite suppression and reduced caloric intake. However, significant reductions in total food consumption increase the risk of inadequate protein intake, and available evidence suggests that a proportion of weight lost on GLP-1 protocols includes lean mass as well as fat. Studies indicate that higher protein intake and resistance exercise during GLP-1 treatment may help preserve skeletal muscle. In this context, monitoring circulating amino acid profiles — particularly BCAA levels and markers sensitive to protein adequacy — may support more personalised nutritional guidance during treatment. Biostarks' Metabolic Health panel was developed with GLP-1 users as a primary use case.

Statins

Statins — broadly prescribed for cardiovascular risk reduction — have been associated with myopathy and muscle-related side effects in a subset of users. The mechanisms are multifactorial and include impaired CoQ10 biosynthesis (via mevalonate pathway inhibition) and potential effects on mitochondrial function in muscle tissue. While statins do not directly impair amino acid absorption, their myopathic effects may alter protein metabolism, muscle catabolism, and nitrogen balance in affected individuals. Patients experiencing statin-associated muscle symptoms represent a population where monitoring amino acid profiles — alongside CoQ10 and mitochondrial markers — may provide additional metabolic context.

Post-Bariatric Surgery

Bariatric procedures substantially alter gastrointestinal anatomy and transit time, frequently compromising protein absorption. Deficiencies in essential amino acids, including methionine, lysine, and threonine, have been documented in post-bariatric patients. Long-term amino acid monitoring is increasingly recognised as a component of post-surgical nutritional follow-up.

Hepatic Encephalopathy and Liver Disease

In advanced liver disease, the Fischer ratio — the molar ratio of BCAAs to aromatic amino acids (phenylalanine + tyrosine) in plasma — becomes clinically relevant. Impaired hepatic metabolism leads to reduced BCAA catabolism and accumulation of aromatic amino acids, contributing to altered neurotransmitter precursor availability. BCAA supplementation in this context has been investigated as a therapeutic strategy to support hepatic function and reduce encephalopathy risk.

6. Why Amino Acids Are Well-Suited for Mass Spectrometry

Accurate quantification of free amino acids in biological matrices — plasma, dried blood spots, urine — is analytically challenging. Many amino acids share similar molecular weights, are present at highly variable concentrations across analytes, and some (such as leucine and isoleucine) are structural isomers that cannot be distinguished without chromatographic separation. These characteristics make immunoassay-based approaches, which dominate routine clinical chemistry for many biomarkers, poorly suited for comprehensive amino acid profiling.

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) addresses these challenges directly:

Chromatographic separation: LC separates amino acids — including structural isomers like leucine and isoleucine — based on their physicochemical properties before mass analysis, eliminating co-elution artefacts.
Characteristic fragmentation: Each amino acid produces specific fragment ions (product ions) upon collision-induced dissociation. Selected reaction monitoring (SRM/MRM) transitions — monitoring the precursor-to-product ion pair — provide both identification and quantification in a single analytical step.
High sensitivity and specificity: LC-MS/MS can quantify amino acids at picomolar to nanomolar concentrations, accommodating the wide dynamic range of the plasma amino acid pool without matrix interference.
Multiplexed measurement: A single LC-MS/MS run can simultaneously quantify 20–40+ amino acids and related metabolites — a throughput not achievable by individual immunoassays without significant resource investment.
Isotope-labelled internal standards: Stable isotope-labelled analogues of each amino acid can be added as internal standards, allowing precise absolute quantification and correcting for matrix effects and extraction variability.

These properties have made LC-MS/MS the method of choice for plasma amino acid profiling in metabolomics research, newborn screening programmes, and increasingly in precision nutrition and health optimisation platforms.

7. Biomarker Mapping: Amino Acids and Measurement

Following the Biostarks framework of connecting biological concept to measurable biomarker to analytical method:

Muscle protein synthesis signalling → Leucine, isoleucine, valine (BCAAs) → plasma free amino acid profiling by LC-MS/MS
Serotonin and NAD⁺ metabolism → Tryptophan → plasma tryptophan quantification by LC-MS/MS
One-carbon / methylation cycle → Methionine → plasma methionine; paired with homocysteine → LC-MS/MS
Catecholamine and thyroid precursor availability → Phenylalanine, tyrosine → plasma phenylalanine:tyrosine ratio by LC-MS/MS
Collagen synthesis and glutathione support → Glycine, cysteine → plasma amino acid profiling by LC-MS/MS
Nitrogen transport and immune fuel → Glutamine → plasma glutamine by LC-MS/MS
Hepatic BCAA metabolism (Fischer ratio) → Leucine + isoleucine + valine vs. phenylalanine + tyrosine → ratio computed from plasma profiling
Overall protein nutritional status → Multiple essential amino acid levels → plasma amino acid panel

Primary biomarkers: Leucine, isoleucine, valine, tryptophan, methionine, phenylalanine, tyrosine, glutamine, glycine, arginine.

Secondary contextual biomarkers: Homocysteine, methylmalonic acid, albumin (as a protein status indicator), creatinine, liver function markers.

Analytical method: LC-MS/MS (plasma or dried blood spot).

8. How Biostarks Can Help

Amino acid measurement at the precision level described above is not typically available through standard clinical panels, which may report only a handful of amino acids — or none — in routine metabolic screens.

Biostarks' Nutrition and Metabolic Health panels cover a broad range of amino acids measured by high-resolution mass spectrometry, providing simultaneous quantification of multiple essential and conditionally essential amino acids from a single at-home dried blood spot sample. This approach enables:

Identification of amino acid imbalances that may not be apparent from dietary records alone
Baseline assessment prior to or during nutritional interventions, pharmacological protocols, or training programmes
Longitudinal tracking of amino acid status in response to dietary changes or supplementation
Contextual interpretation alongside related biomarkers including homocysteine, metabolic markers, and micronutrient status

For individuals on GLP-1 protocols, athletes optimising recovery nutrition, or anyone seeking a deeper understanding of their metabolic baseline, amino acid profiling adds a layer of precision that complements broader health biomarker panels.

References

Protein and amino acids for athletes — Journal of Sports Sciences — R.J. Maughan & L.M. Burke — (2002) — Source
Leucine regulates translation initiation of protein synthesis in skeletal muscle after exercise — Journal of Nutrition — L.S. Jefferson & S.R. Kimball — (2003) — Source
Branched-chain amino acids and metabolic disease — Current Opinion in Clinical Nutrition & Metabolic Care — C.B. Newgard — (2012) — Source
Tryptophan and the serotonin–kynurenine balance: a review — Nutrients — A. Cervenka et al. — (2017) — Source
Plasma amino acid profiling by liquid chromatography–tandem mass spectrometry: method development and clinical application — Analytical Chemistry — B.G. Keevil et al. — (2009) — Source
Glutamine: metabolism and immune function, supplementation and clinical translation — Nutrients — P. Cruzat et al. — (2018) — Source
GLP-1 receptor agonists and the risk of lean mass loss: a review of current evidence — Obesity Reviews — T. Wilding et al. — (2023) — Source
Amino acid metabolism and statin myopathy — Journal of Clinical Lipidology — R.S. Rosenson — (2014) — Source
Fischer ratio and branched-chain amino acids in hepatic encephalopathy — Hepatology — H. Riggio et al. — (2010) — Source